safingol has been researched along with Thrombopenia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Casper, ES; Kelsen, DP; Mullen, E; Saltz, L; Schwartz, GK; Spiess, T; Storniolo, AM; Venuti, R; Ward, D; Woodworth, J; Zervos, P | 1 |
1 trial(s) available for safingol and Thrombopenia
Article | Year |
---|---|
A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Pilot Projects; Protein Kinase C; Regression Analysis; Sphingosine; Thrombocytopenia | 1997 |